Adenocarcinoma of the cervical esophagus arising within a long segment of Barrett’s metaplasia

A 53-year-old man was referred to the endoscopy unit for evaluation of noncardiac chest pain. He did not report dysphagia, gastroesophageal reflux disease symptoms, or weight loss. His medical record included hyperlipidemia and duodenal peptic ulcer disease along with a history of smoking (20 pack-years). Upper endoscopy showed a long segment of columnar-type epithelium extending from the top of the gastric folds (35 cm from incisors) (Fig. 1a) to the cervical esophagus (20 cm), corresponding to C15M15 (Prague classification) Barrett’s esophagus (BE). The distal and middle part of the BE segment was inconspicuous both in white-light and narrow-band imaging (Fig. 1b). However, at the top of the Barrett’s metaplasia, just below the upper esophageal sphincter, a protruded ulcerated tumor was identified (Fig. 1c, Video 1). Tumor biopsies confirmed a well-differentiated adenocarcinoma on a background of intestinal metaplasia. Positron emission tomography-computed tomography scan showed a marked increase in metabolic activity in the cervical esophagus without evidence of metastatic spread (Fig. 1d).

Although squamous cell carcinoma (SCC) accounts for nearly 90% of esophageal cancers worldwide, the incidence of esophageal adenocarcinoma (EAC) has already surpassed that of SCC in several regions of North America and Europe [1]. Similarly to its precursor condition, BE, EAC is typically located in the distal esophagus where inflammation from gastric acid reflux is most profound. Carcinoma of the cervical esophagus is rare (2%–10%) and nearly all of these tumors are SCC in origin (~95%) [2]. Reports of adenocarcinomas in this region are confined to cases arising within inlet patches [3, 4], rather than BE. While neoplastic changes preferentially occur in the proximal parts of BE segments [5], the extension of Barrett’s metaplasia rarely reaches the cervical esophagus. The optimal management of such tumors is not established; however, surgery remains the mainstay treatment for adenocarcinoma. In our case, a multidisciplinary decision for pharyngo-laryngo-esophagectomy with neoadjuvant chemoradiotherapy was taken.

The authors declare that they have no conflict of interest.

Władysław Januszewicz1,2, Krzysztof Trzebinski1, Małgorzata Lenarcik3, Anna Cencelewicz-Lesikow2, Michał F. Kaminski1,2,4, Jarosław Regula1,2

1 Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Centre for Postgraduate Education, Warsaw, Poland
2 Department of Oncological Gastroenterology, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Competing interests

The authors

Fig. 1 Images at presentation. a Distal esophagus and the top of the gastric folds at 35 cm from the incisors (star). b The middle part of the Barrett’s esophagus segment without visible abnormalities on white-light imaging. c Top of the Barrett segment with a protruded and partially ulcerated tumor at 20 cm from the incisors; the border between columnar and squamous epithelium (Z-line) is clearly visible (arrowhead). d Positron emission tomography-computed tomography showing a marked increase in metabolic activity in the cervical esophagus (sagittal and coronal planes).
Video 1: High-definition white-light endoscopy showing the whole length of the esophagus, from the gastroesophageal junction and along the long segment of Barrett’s esophagus to the proximal esophagus, where a protruded, partially ulcerated tumor was identified at 20 cm from the incisors. Narrow-band imaging helped to delineate the lesion.

References